Arcturus Therapeutics (ARCT) PT Lowered to $33 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to Arcturus Therapeutics (ARCT) PT Lowered to $33 at H.C. Wainwright
January 25, 2022 8:00 AM EST
Analysis of sera from Phase 1/2 booster study demonstrates 54- and 47-fold increases in geometric mean neutralizing antibody titers against the Omicron variant at Day 29 for ARCT-154 (5 mcg) and ARCT-165 (5 mcg) respectively
SAN DIEGO--(BUSINESS WIRE)--
Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced new data from clinical development programs for ARCT-154 and ARCT-165, its investigational, next-generation, self-amplifying mRNA vaccine candidates targeting variants of... More
January 24, 2022 8:00 AM EST
Full cohort data from the ARCT-154 (5 mcg) arm of the ongoing Phase 1/2 booster study shows 30-fold increase in neutralizing antibody geometric mean concentrations against SARS-CoV-2 at Day 15 post-boost, maintained at 28-fold increase at Day 29, using a validated pseudovirus microneutralization (MNT) assay
Robust neutralizing antibody responses observed post-boost for both ARCT-154 (5 mcg) and ARCT-165 (5 mcg) against several variants of concern and variants of interest in a surrogate virus neutralization (sVNT) assay
SAN DIEGO--(BUSINESS WIRE)--
Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage... More
